ReviewSports medicine international open2026
Unlocking Performance: Pharmacogenomic Insights for Athletes.
Review in Sports medicine international open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenomics is the study of how genetic differences influence drug responses, offering a safer and more effective prescribing model. While pharmacogenomics is well-established in specialties such as oncology and psychiatry, its application in sports medicine remains limited. Athletes frequently use medications such as nonsteroidal anti-inflammatory drugs, opioids, and selective serotonin reuptake inhibitors, and these medications have well-documented gene-drug interactions. This review explores pharmacogenomics considerations for these commonly used substances in athletic populations, emphasizing how genetic variability in drug-metabolizing enzymes, including CYP2C9, CYP2D6, and CYP2C19, can impact medication efficacy and side effect risks. We summarize current evidence, highlight clinical guidelines, and outline how pharmacogenomics-guided prescribing could improve athlete care. By integrating pharmacogenomics into sports medicine, clinicians can tailor medication strategies to each athlete's genetic profile, supporting both health and performance. Broader adoption will require increased clinician education, interdisciplinary collaboration, and research specific to athletic populations, but pharmacogenomics offers a promising tool for advancing individualized, precision-based athlete healthcare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.